Exposure-response relationship between transportation noise and cardiovascular disease outcomes: a systematic review and meta-regression analysis.

J Expo Sci Environ EpidemiolApr 6, 2026 (epub)
Clinical ResearchCardiologyOpen access

Elia Gonzato, Tessa M I Haverkate, Susanne Breitner-Busch et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-regression analysed cohort and case-control evidence on long-term road, railway, and aircraft noise exposure and cardiovascular outcomes in general populations. Twenty-six studies met the eligibility criteria. In conventional analyses, road traffic noise was associated with a 1% increase in combined stroke incidence and mortality (RR = 1.01, 95%CI: 1.00-1.02), while railway noise was associated with a 1% increase in myocardial infarction outcomes (RR = 1.01, 95%CI: 1.01-1.01). Estimates differed under the Burden of Proof framework, and evidence varied across the twelve risk-outcome pairs examined.

Key findings

  • Road traffic noise was associated with a 1% increase in combined stroke incidence and mortality (RR = 1.01, 95%CI: 1.00-1.02, p-value = 0.04).
  • Railway noise was associated with a 1% increase in myocardial infarction outcomes (RR = 1.01, 95%CI: 1.01-1.01, p-value < 0.0001).
  • Under the Burden of Proof framework, estimates were RR = 1.05 (95%UI: 1.03-1.07) for road noise and stroke, and RR = 1.16 (95%UI: 1.07-1.26) for railway noise and myocardial infarction.
  • Across twelve risk-outcome pairs, five showed no evidence of association, four showed weak evidence, and the remainder lacked credible evidence or did not meet Burden of Proof criteria.

Why it matters

Transportation noise is a potentially relevant environmental exposure in cardiovascular disease burden assessment. This review updates the evidence base and shows that estimated associations depend on the method used to derive exposure-response functions. The variation in evidence across noise sources and outcomes underscores the importance of interpreting individual risk estimates in light of their evidential strength and analytical framework.

What to keep in mind

Evidence was uneven across the twelve risk-outcome pairs: several showed no or weak association, while others lacked credible evidence or did not meet Burden of Proof criteria.

Source

Published in J Expo Sci Environ Epidemiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.